{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-008257","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.454651+00:00","generated_at":"2026-05-16T22:02:02.463704+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aethlon Medical Q2 fiscal 2025: operating loss narrows to $1.5M, clinical trial advances","bullets":["Cash balance $5.8M at Sept 30, 2025; operating expenses down 48% YoY to $1.5M.","Operating loss narrowed to $1.5M from $2.8M in the prior-year quarter.","Nasdaq compliance resolved; AEMD remains listed on the Capital Market.","Recruitment began for Cohort 2 of Australian Hemopurifier oncology trial with pembrolizumab/nivolumab.","Long COVID research with UCSF continues; manuscript in preparation for peer-reviewed journal."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-008257","json":"https://secwatch.observer/filing/0001683168-25-008257.json","markdown":"https://secwatch.observer/filing/0001683168-25-008257.md","text":"https://secwatch.observer/filing/0001683168-25-008257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316825008257/0001683168-25-008257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316825008257/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:02:02.463704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}